Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.
Journal: Hepatology (Baltimore, Md.)
Published: December 04, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
Journal: Journal of hepatology
Published: July 23, 2024
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Journal: The lancet. Gastroenterology & hepatology
Published: May 18, 2022
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Journal: The lancet. Gastroenterology & hepatology
Published: July 10, 2019
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Journal: JAMA
Published: May 06, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Journal: Hepatology (Baltimore, Md.)
Published: December 10, 2014
Showing 1-6 of 6
Last Updated: 09/26/2026